<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />

<meta name="viewport" content="width=device-width, initial-scale=1" />



<title>Cancer type considerations for COSMIC signatures</title>



<style type="text/css">code{white-space: pre;}</style>
<style type="text/css" data-origin="pandoc">
a.sourceLine { display: inline-block; line-height: 1.25; }
a.sourceLine { pointer-events: none; color: inherit; text-decoration: inherit; }
a.sourceLine:empty { height: 1.2em; }
.sourceCode { overflow: visible; }
code.sourceCode { white-space: pre; position: relative; }
div.sourceCode { margin: 1em 0; }
pre.sourceCode { margin: 0; }
@media screen {
div.sourceCode { overflow: auto; }
}
@media print {
code.sourceCode { white-space: pre-wrap; }
a.sourceLine { text-indent: -1em; padding-left: 1em; }
}
pre.numberSource a.sourceLine
  { position: relative; left: -4em; }
pre.numberSource a.sourceLine::before
  { content: attr(data-line-number);
    position: relative; left: -1em; text-align: right; vertical-align: baseline;
    border: none; pointer-events: all; display: inline-block;
    -webkit-touch-callout: none; -webkit-user-select: none;
    -khtml-user-select: none; -moz-user-select: none;
    -ms-user-select: none; user-select: none;
    padding: 0 4px; width: 4em;
    color: #aaaaaa;
  }
pre.numberSource { margin-left: 3em; border-left: 1px solid #aaaaaa;  padding-left: 4px; }
div.sourceCode
  {  }
@media screen {
a.sourceLine::before { text-decoration: underline; }
}
code span.al { color: #ff0000; font-weight: bold; } /* Alert */
code span.an { color: #60a0b0; font-weight: bold; font-style: italic; } /* Annotation */
code span.at { color: #7d9029; } /* Attribute */
code span.bn { color: #40a070; } /* BaseN */
code span.bu { } /* BuiltIn */
code span.cf { color: #007020; font-weight: bold; } /* ControlFlow */
code span.ch { color: #4070a0; } /* Char */
code span.cn { color: #880000; } /* Constant */
code span.co { color: #60a0b0; font-style: italic; } /* Comment */
code span.cv { color: #60a0b0; font-weight: bold; font-style: italic; } /* CommentVar */
code span.do { color: #ba2121; font-style: italic; } /* Documentation */
code span.dt { color: #902000; } /* DataType */
code span.dv { color: #40a070; } /* DecVal */
code span.er { color: #ff0000; font-weight: bold; } /* Error */
code span.ex { } /* Extension */
code span.fl { color: #40a070; } /* Float */
code span.fu { color: #06287e; } /* Function */
code span.im { } /* Import */
code span.in { color: #60a0b0; font-weight: bold; font-style: italic; } /* Information */
code span.kw { color: #007020; font-weight: bold; } /* Keyword */
code span.op { color: #666666; } /* Operator */
code span.ot { color: #007020; } /* Other */
code span.pp { color: #bc7a00; } /* Preprocessor */
code span.sc { color: #4070a0; } /* SpecialChar */
code span.ss { color: #bb6688; } /* SpecialString */
code span.st { color: #4070a0; } /* String */
code span.va { color: #19177c; } /* Variable */
code span.vs { color: #4070a0; } /* VerbatimString */
code span.wa { color: #60a0b0; font-weight: bold; font-style: italic; } /* Warning */

</style>
<script>
// apply pandoc div.sourceCode style to pre.sourceCode instead
(function() {
  var sheets = document.styleSheets;
  for (var i = 0; i < sheets.length; i++) {
    if (sheets[i].ownerNode.dataset["origin"] !== "pandoc") continue;
    try { var rules = sheets[i].cssRules; } catch (e) { continue; }
    for (var j = 0; j < rules.length; j++) {
      var rule = rules[j];
      // check if there is a div.sourceCode rule
      if (rule.type !== rule.STYLE_RULE || rule.selectorText !== "div.sourceCode") continue;
      var style = rule.style.cssText;
      // check if color or background-color is set
      if (rule.style.color === '' && rule.style.backgroundColor === '') continue;
      // replace div.sourceCode by a pre.sourceCode rule
      sheets[i].deleteRule(j);
      sheets[i].insertRule('pre.sourceCode{' + style + '}', j);
    }
  }
})();
</script>



<style type="text/css">body {
background-color: #fff;
margin: 1em auto;
max-width: 700px;
overflow: visible;
padding-left: 2em;
padding-right: 2em;
font-family: "Open Sans", "Helvetica Neue", Helvetica, Arial, sans-serif;
font-size: 14px;
line-height: 1.35;
}
#TOC {
clear: both;
margin: 0 0 10px 10px;
padding: 4px;
width: 400px;
border: 1px solid #CCCCCC;
border-radius: 5px;
background-color: #f6f6f6;
font-size: 13px;
line-height: 1.3;
}
#TOC .toctitle {
font-weight: bold;
font-size: 15px;
margin-left: 5px;
}
#TOC ul {
padding-left: 40px;
margin-left: -1.5em;
margin-top: 5px;
margin-bottom: 5px;
}
#TOC ul ul {
margin-left: -2em;
}
#TOC li {
line-height: 16px;
}
table {
margin: 1em auto;
border-width: 1px;
border-color: #DDDDDD;
border-style: outset;
border-collapse: collapse;
}
table th {
border-width: 2px;
padding: 5px;
border-style: inset;
}
table td {
border-width: 1px;
border-style: inset;
line-height: 18px;
padding: 5px 5px;
}
table, table th, table td {
border-left-style: none;
border-right-style: none;
}
table thead, table tr.even {
background-color: #f7f7f7;
}
p {
margin: 0.5em 0;
}
blockquote {
background-color: #f6f6f6;
padding: 0.25em 0.75em;
}
hr {
border-style: solid;
border: none;
border-top: 1px solid #777;
margin: 28px 0;
}
dl {
margin-left: 0;
}
dl dd {
margin-bottom: 13px;
margin-left: 13px;
}
dl dt {
font-weight: bold;
}
ul {
margin-top: 0;
}
ul li {
list-style: circle outside;
}
ul ul {
margin-bottom: 0;
}
pre, code {
background-color: #f7f7f7;
border-radius: 3px;
color: #333;
white-space: pre-wrap; 
}
pre {
border-radius: 3px;
margin: 5px 0px 10px 0px;
padding: 10px;
}
pre:not([class]) {
background-color: #f7f7f7;
}
code {
font-family: Consolas, Monaco, 'Courier New', monospace;
font-size: 85%;
}
p > code, li > code {
padding: 2px 0px;
}
div.figure {
text-align: center;
}
img {
background-color: #FFFFFF;
padding: 2px;
border: 1px solid #DDDDDD;
border-radius: 3px;
border: 1px solid #CCCCCC;
margin: 0 5px;
}
h1 {
margin-top: 0;
font-size: 35px;
line-height: 40px;
}
h2 {
border-bottom: 4px solid #f7f7f7;
padding-top: 10px;
padding-bottom: 2px;
font-size: 145%;
}
h3 {
border-bottom: 2px solid #f7f7f7;
padding-top: 10px;
font-size: 120%;
}
h4 {
border-bottom: 1px solid #f7f7f7;
margin-left: 8px;
font-size: 105%;
}
h5, h6 {
border-bottom: 1px solid #ccc;
font-size: 105%;
}
a {
color: #0033dd;
text-decoration: none;
}
a:hover {
color: #6666ff; }
a:visited {
color: #800080; }
a:visited:hover {
color: #BB00BB; }
a[href^="http:"] {
text-decoration: underline; }
a[href^="https:"] {
text-decoration: underline; }

code > span.kw { color: #555; font-weight: bold; } 
code > span.dt { color: #902000; } 
code > span.dv { color: #40a070; } 
code > span.bn { color: #d14; } 
code > span.fl { color: #d14; } 
code > span.ch { color: #d14; } 
code > span.st { color: #d14; } 
code > span.co { color: #888888; font-style: italic; } 
code > span.ot { color: #007020; } 
code > span.al { color: #ff0000; font-weight: bold; } 
code > span.fu { color: #900; font-weight: bold; } 
code > span.er { color: #a61717; background-color: #e3d2d2; } 
</style>




</head>

<body>




<h1 class="title toc-ignore">Cancer type considerations for COSMIC signatures</h1>



<p>The cancereffectsizeR trinuc_mutation_rates uses mutational signature extraction to calculate relative trinucleotide-specific SNV mutation rates for each tumor in the input data. The “signatures_to_remove” option allows some signatures to be excluded from this analysis, which means each tumor will receive a weight of 0 for these signatures (i.e., 0% of the tumor’s SNVs are attributable to these signatures). By default, SBS25 is excluded because it’s considered dubious and is specific to Hodgkin’s lymphoma cell lines. You can override this behavior by setting <code>signatures_to_remove = &quot;none&quot;</code>.</p>
<p>In <a href="https://doi.org/10.1038/s41586-020-1943-3">Alexandrov 2020</a>, the paper introducing the latest COSMIC mutational signatures (COSMICv3), there are some signatures that do not appear in certain cancer types. Therefore, you may wish to exclude those signatures during mutational signature analysis of your data.</p>
<p>There are also a few signatures associated with certain chemotherapy drugs (SBS31, SBS32, SBS35), so if you are confident that your sample is treatment-naive, you may wish to exclude these.</p>
<p>Note that while some COSMIC signatures are believed to represent sequencing artifacts, it’s not recommended to remove these from analysis, because cancereffectsizeR already has special handling of these signatures to determine relative rates of true mutational processes in tumors.</p>
<p>To get a list of signatures to exclude based on cancer type and treatment status, you can use <code>suggest_cosmic_v3_signatures_to_remove()</code>.</p>
<div class="sourceCode" id="cb1"><pre class="sourceCode r"><code class="sourceCode r"><a class="sourceLine" id="cb1-1" data-line-number="1">  <span class="kw">suggest_cosmic_v3_signatures_to_remove</span>(<span class="dt">cancer_type =</span> <span class="st">&quot;BRCA&quot;</span>, <span class="dt">treatment_naive =</span> <span class="ot">TRUE</span>)</a>
<a class="sourceLine" id="cb1-2" data-line-number="2">  <span class="kw">suggest_cosmic_v3_signatures_to_remove</span>(<span class="dt">cancer_type =</span> <span class="st">&quot;Kidney-RCC&quot;</span>)</a></code></pre></div>
<p>The cancer type recommendations are based on Extended Data Figure 5 of Alexandrov 2020. The first two columns of the table below, also based on that figure, give the labels accepted by the <code>cancer_type</code> argument.</p>
<p>Before excluding signatures, make sure your data set does not contain tumors from multiple PCAWG categories. For example, TCGA HNSC (head and neck cancer) includes oral cancers, which are listed separately here as Oral-SCC, so excluding all signatures that do not appear in Head-SCC (such as SBS29, tobacco chewing) would not be appropriate.</p>
<table class="table table-condensed">
<thead>
<tr>
<th style="text-align:right;">
PCAWG
</th>
<th style="text-align:right;">
Applicable_TCGA
</th>
<th style="text-align:right;">
Number_of_tumors
</th>
<th style="text-align:right;">
Description
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:right;">
ALL
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
33
</td>
<td style="text-align:right;">
acute lymphoblastic leukemia
</td>
</tr>
<tr>
<td style="text-align:right;">
Biliary-AdenoCA
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
173
</td>
<td style="text-align:right;">
biliary adenocarcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Bladder-TCC
</td>
<td style="text-align:right;">
BLCA
</td>
<td style="text-align:right;">
369
</td>
<td style="text-align:right;">
bladder transitional cell carcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Bone-Osteosarc
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
36
</td>
<td style="text-align:right;">
sarcoma, bone
</td>
</tr>
<tr>
<td style="text-align:right;">
Bone-Other
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
18
</td>
<td style="text-align:right;">
Paper vague; presumably bone cartilaginous neoplasm osteoblastoma, bone osteofibrous dysplasia, bone neoplasm epithelioid
</td>
</tr>
<tr>
<td style="text-align:right;">
Breast
</td>
<td style="text-align:right;">
BRCA
</td>
<td style="text-align:right;">
834
</td>
<td style="text-align:right;">
breast adenocarcinoma, ductal carcinoma in situ, breast lobular carcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Cervix-AdenoCA
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
204
</td>
<td style="text-align:right;">
cervix adenocarcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
CNS-GBM
</td>
<td style="text-align:right;">
GBM
</td>
<td style="text-align:right;">
100
</td>
<td style="text-align:right;">
CNS glioblastoma
</td>
</tr>
<tr>
<td style="text-align:right;">
CNS-LGG
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
27
</td>
<td style="text-align:right;">
CNS lower-grade glioma
</td>
</tr>
<tr>
<td style="text-align:right;">
CNS-Medullo
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
185
</td>
<td style="text-align:right;">
CNS medulloblastoma
</td>
</tr>
<tr>
<td style="text-align:right;">
CNS-Oligo
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
18
</td>
<td style="text-align:right;">
CNS oligodenroglioma
</td>
</tr>
<tr>
<td style="text-align:right;">
CNS-PiloAstro
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
48
</td>
<td style="text-align:right;">
CNS pilocytic astrocytomaE:E
</td>
</tr>
<tr>
<td style="text-align:right;">
ColoRect-AdenoCA
</td>
<td style="text-align:right;">
COAD, READ
</td>
<td style="text-align:right;">
719
</td>
<td style="text-align:right;">
colorectal adenocarcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Eso-AdenoCA
</td>
<td style="text-align:right;">
ESCA
</td>
<td style="text-align:right;">
347
</td>
<td style="text-align:right;">
esophagus adenocarcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Eso-SCC
</td>
<td style="text-align:right;">
ESCA
</td>
<td style="text-align:right;">
160
</td>
<td style="text-align:right;">
esophagus squamous cell carcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Ewings
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
85
</td>
<td style="text-align:right;">
Ewing’s sarcoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Eye-Melanoma
</td>
<td style="text-align:right;">
UVM
</td>
<td style="text-align:right;">
13
</td>
<td style="text-align:right;">
uveal melanoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Head-SCC
</td>
<td style="text-align:right;">
HNSC
</td>
<td style="text-align:right;">
313
</td>
<td style="text-align:right;">
head-and-neck squamous cell carcinoma (note HNSC also includes some oral-SCC)
</td>
</tr>
<tr>
<td style="text-align:right;">
Kidney-ChRCC
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
46
</td>
<td style="text-align:right;">
kidney chromophobe renal cell carcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Kidney-Papillary
</td>
<td style="text-align:right;">
KIRP
</td>
<td style="text-align:right;">
21
</td>
<td style="text-align:right;">
papillary renal cell carcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Kidney-RCC
</td>
<td style="text-align:right;">
KIRC
</td>
<td style="text-align:right;">
184
</td>
<td style="text-align:right;">
kidney renal cell carcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Liver-HCC
</td>
<td style="text-align:right;">
LIHC
</td>
<td style="text-align:right;">
489
</td>
<td style="text-align:right;">
liver hepatocellular carcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Lung-AdenoCA
</td>
<td style="text-align:right;">
LUAD
</td>
<td style="text-align:right;">
438
</td>
<td style="text-align:right;">
lung adenocarcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Lung-SCC
</td>
<td style="text-align:right;">
LUSC
</td>
<td style="text-align:right;">
350
</td>
<td style="text-align:right;">
lung squamous cell carcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Lymph-BNHL
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
135
</td>
<td style="text-align:right;">
lymphoid mature B-cell lymphoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Lymph-CLL
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
171
</td>
<td style="text-align:right;">
lymphoid chronic lymphocytic leukemia
</td>
</tr>
<tr>
<td style="text-align:right;">
Myeloid-AML
</td>
<td style="text-align:right;">
LAML
</td>
<td style="text-align:right;">
106
</td>
<td style="text-align:right;">
acute myeloid leukemia
</td>
</tr>
<tr>
<td style="text-align:right;">
Myeloid-MDS/MPN
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
43
</td>
<td style="text-align:right;">
myelodysplastic syndrome and myeloproliferative neoplasm
</td>
</tr>
<tr>
<td style="text-align:right;">
Oral-SCC
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
52
</td>
<td style="text-align:right;">
oral squamous cell carcinoma (note some TCGA HNSC are oral)
</td>
</tr>
<tr>
<td style="text-align:right;">
Ovary-AdenoCA
</td>
<td style="text-align:right;">
OV
</td>
<td style="text-align:right;">
149
</td>
<td style="text-align:right;">
ovary adenocarcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Panc-AdenoCA
</td>
<td style="text-align:right;">
PAAD
</td>
<td style="text-align:right;">
357
</td>
<td style="text-align:right;">
pancreatic adenocarcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Panc-Endocrine
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
95
</td>
<td style="text-align:right;">
pancreatic neuroendocrine tumor
</td>
</tr>
<tr>
<td style="text-align:right;">
Prost-AdenoCA
</td>
<td style="text-align:right;">
PRAD
</td>
<td style="text-align:right;">
407
</td>
<td style="text-align:right;">
prostate adenocarcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Sarcoma
</td>
<td style="text-align:right;">
SARC
</td>
<td style="text-align:right;">
26
</td>
<td style="text-align:right;">
sarcoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Sarcoma-bone
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
59
</td>
<td style="text-align:right;">
paper unclear; perhaps osteosarcoma and other sarcomas combined?
</td>
</tr>
<tr>
<td style="text-align:right;">
Skin-BCC
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
117
</td>
<td style="text-align:right;">
skin basal cell carcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Skin-Melanoma
</td>
<td style="text-align:right;">
SKCM
</td>
<td style="text-align:right;">
809
</td>
<td style="text-align:right;">
skin melanoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Skin-SCC
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
41
</td>
<td style="text-align:right;">
skin squamous cell carcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
SoftTissue-Leiomyo
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
15
</td>
<td style="text-align:right;">
leiomyosarcoma soft tissue
</td>
</tr>
<tr>
<td style="text-align:right;">
SoftTissue-Liposarc
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
19
</td>
<td style="text-align:right;">
liposarcoma soft tissue
</td>
</tr>
<tr>
<td style="text-align:right;">
Stomach-AdenoCA
</td>
<td style="text-align:right;">
(none)
</td>
<td style="text-align:right;">
452
</td>
<td style="text-align:right;">
stomach adenocarcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Thy-AdenoCA
</td>
<td style="text-align:right;">
THCA
</td>
<td style="text-align:right;">
67
</td>
<td style="text-align:right;">
thyroid low-grade adenocarcinoma
</td>
</tr>
<tr>
<td style="text-align:right;">
Uterus-AdenoCA
</td>
<td style="text-align:right;">
UCEC
</td>
<td style="text-align:right;">
291
</td>
<td style="text-align:right;">
uterus adenocarcinoma
</td>
</tr>
</tbody>
</table>



<!-- code folding -->


<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
